UCL has been ranked third in the UK and seventh in Europe in the Royal Academy of Engineering's Spotlight on Spinouts 2026 report, underlining UCL's strength in helping researchers turn breakthrough discoveries into high-growth companies with real-world impact.
The report highlights the success of UCL and its commercialisation arm, UCLB, in translating its world-leading research and innovation - in areas such as medicine, artificial intelligence and green energy - into ambitious ventures with global potential.
Providing a comprehensive, data-driven analysis of the UK spinout ecosystem since 2010, it assesses performance across company creation, funding, sector focus, exits and equity structures in both the UK and Europe.
The UK continues to lead Europe in spinout value creation, with more than 2,000 spinouts generating around £49bn since 2010. The report shows that 96% of this value comes from deep tech companies, particularly in life sciences, AI and quantum. It also finds that spinouts progress to later funding stages at least as strongly as, and in some cases more effectively than, the wider tech sector.
Within this context, UCL spinouts have raised close to £2bn in funding, created approximately £5.5bn in value and produced 64 venture capital-backed companies. These figures reinforce UCL's position as a leading centre for deep tech commercialisation and highlight UCLB's role in building and supporting a strong pipeline of high-growth ventures.
UCL's particular strength in life sciences and health-related deep tech, where its exit performance is especially notable: UCL accounts for seven of the UK's top 20 spinout exits in the past decade, second only to Oxford.
Further, as part of the 'Golden Triangle' cluster of Oxford, Cambridge and London, UCL plays a central role in one of Europe's most dynamic innovation ecosystems.
Commenting, Professor Geraint Rees, Vice-Provost (Research, Innovation & Global Engagement), said: "UCL and UCLB have a strong track record of turning breakthrough science into high‑growth companies, including cancer therapy pioneers such as Autolus and Orchard Therapeutics, which are developing gene therapies for rare diseases.
"What we're seeing in London - particularly around Euston's Knowledge Quarter - is the convergence of world‑class research, entrepreneurial talent and the infrastructure needed to scale. This ecosystem is accelerating the journey from discovery to real‑world impact."
Dr Anne Lane, CEO of UCL Business, said: "UCL's performance in this year's Spotlight on Spinouts report reflects the university's ability to translate world-leading research into ventures with global potential. It also underlines the importance of strong commercialisation support. At UCLB, we work closely with founders to protect and develop their ideas, build investable businesses, and ensure that breakthrough innovation achieves meaningful real-world impact."
The ranking reflects UCL's long-standing strength in research commercialisation and UCLB's role in supporting founders to protect intellectual property, shape commercial strategies and build sustainable, investment-ready businesses. It also points to the opportunity for UCL to close the scale gap with Oxford and Cambridge, while continuing to evolve its commercialisation model to remain globally competitive.
One of UCL's standout success stories is Autolus Therapeutics, which has pioneered an evolution of immunotherapy for treating acute lymphoblastic leukaemia.
This 'living medicine' approach uses a patient's own immune cells, reprogrammed to recognise and destroy cancer cells while helping prevent recurrence.
Supported early on through Proof of Concept funding, the company has raised more than $1.1bn since incorporation, employs over 450 people, and has opened a state-of-the-art manufacturing facility, The Nucleus, in Stevenage. UCLB supported Autolus from its inception, helping establish the spinout, manage its intellectual property and build strategic partnerships.
Across life sciences, healthcare, artificial intelligence, advanced materials and climate innovation, UCLB spinouts are tackling major global challenges while creating economic value and delivering benefits for patients, communities and industry.
The findings underline the critical role of strong commercialisation support in turning research excellence into real-world outcomes - a role UCLB continues to play across UCL's innovation pipeline.
